An open-label, 6-month study of allopurinol safety in gout: The LASSO study

作者
Michael A. Becker,David Fitzpatrick,Hyon K. Choi,Nicola Dalbeth,Chris M. Storgard,Matt Cravets,Scott Baumgartner
出处
期刊:Seminars in Arthritis and Rheumatism [Elsevier BV]
卷期号:45 (2): 174-183 被引量:107
标识
DOI:10.1016/j.semarthrit.2015.05.005
摘要

OBJECTIVES: Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout. To achieve serum uric acid (sUA) concentrations associated with clinical benefit, allopurinol is serially uptitrated with sUA monitoring. Suboptimal dosing is a key contributor to poor clinical outcomes, but few data are available on the safety and efficacy of dose-titrated allopurinol, particularly at doses > 300 mg/d. The objective of this open-label study was to investigate the safety and efficacy of allopurinol under conditions where investigators were encouraged to titrate to optimal, medically appropriate doses. METHODS: Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) was a large, 6-month, multicenter study of allopurinol (NCT01391325). Adults meeting American Rheumatism Association Criteria for Classification of Acute Arthritis of Primary Gout and ≥ 2 gout flares in the previous year were eligible. Investigators were encouraged (but not required) to titrate allopurinol doses to achieve target sUA < 6.0mg/dL. The primary objective was evaluation of the safety of dose-titrated allopurinol by clinical and laboratory examinations at monthly visits. Secondary objectives included sUA-lowering efficacy and gout flare frequency. RESULTS: Of 1735 patients enrolled, 1732 received ≥ 1 allopurinol doses. The maximal daily allopurinol dose during study was < 300 mg in 14.4%, 300 mg in 65.4%, and > 300 mg in 20.2% of patients; dosing duration was 115.5, 152.0, and 159.7 days, respectively. Overall, baseline demographic characteristics and comorbidity rates were similar across these three categories, but patients receiving > 300-mg maximal dose had more severe gout. Treatment-emergent adverse events possibly related to allopurinol occurred in 15.2%, 9.5%, and 11.4% of patients in the < 300-, 300-, and > 300-mg categories, respectively. Rash incidence was low (1.5%) and allopurinol hypersensitivity syndrome was not reported. No clinically meaningful changes occurred in laboratory values. sUA < 6.0mg/dL at month 6 was achieved by 35.9% of patients overall: 22.4%, 35.0%, and 48.3% in dosing categories < 300, 300, and > 300 mg, respectively. CONCLUSIONS: This large multicenter study found that the allopurinol dose-titration strategy was well tolerated, without new safety signals emerging over 6 months. However, despite encouragement to treat to target, significant proportions of patients did not achieve target sUA.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
无花果的应助被LV采纳,获得10
1秒前
1秒前
1秒前
李健的应助被suo采纳,获得10
1秒前
陶醉白梅完成签到,获得积分10
1秒前
2秒前
Owen的应助被hhb采纳,获得10
2秒前
斯文败类的应助被珍珠采纳,获得10
2秒前
123完成签到,获得积分20
2秒前
Amber完成签到,获得积分10
2秒前
hys发布了新的文献求助10
2秒前
科研通AI6.3的应助被新帅采纳,获得10
2秒前
李健的小迷弟的应助被franklove采纳,获得10
3秒前
gc完成签到,获得积分10
3秒前
路口发布了新的文献求助10
3秒前
丘比特的应助被黎颜采纳,获得10
3秒前
echo完成签到,获得积分10
3秒前
gaw2008完成签到,获得积分10
3秒前
脑洞疼的应助被panpan采纳,获得10
4秒前
4秒前
酷酷柚子发布了新的文献求助10
4秒前
4秒前
4秒前
pgr发布了新的文献求助10
4秒前
田帅发布了新的文献求助10
4秒前
4秒前
鲸落小小的应助被温水云采纳,获得10
5秒前
5秒前
缓慢的一凤完成签到,获得积分10
6秒前
水煮电吹风的应助被Code_king采纳,获得10
6秒前
嘻嘻哈哈的应助被Code_king采纳,获得10
6秒前
斯文败类的应助被沉静土豆采纳,获得10
6秒前
嘻嘻哈哈的应助被Code_king采纳,获得10
6秒前
嘻嘻哈哈的应助被Code_king采纳,获得10
7秒前
水煮电吹风的应助被Code_king采纳,获得10
7秒前
水煮电吹风的应助被Code_king采纳,获得10
7秒前
冬藏发布了新的文献求助10
7秒前
水煮电吹风的应助被Code_king采纳,获得10
7秒前
水煮电吹风的应助被Code_king采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460